Pharming Group outlines 2025 revenue guidance of $315M to $335M driven by RUCONEST and Joenja growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 13 2025
0mins
Source: SeekingAlpha
Financial Performance: Pharming Group reported a 21% revenue growth in 2024, reaching $297 million, with RUCONEST and Joenja driving significant increases in sales. The company also provided optimistic guidance for 2025, projecting revenues between $315 million and $335 million.
Strategic Outlook: Management emphasized plans to expand Joenja's market presence and integrate the recent Abliva acquisition while addressing competitive challenges in the HAE market. Analysts expressed cautious optimism regarding Joenja's growth potential amidst concerns about patient enrollments and competition.
Analyst Views on PHAR
Wall Street analysts forecast PHAR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAR is 39.50 USD with a low forecast of 37.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 19.930
Low
37.00
Averages
39.50
High
42.00
Current: 19.930
Low
37.00
Averages
39.50
High
42.00
About PHAR
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
